AbbVie Inc. buy AI_Picker
Start price
26.06.24
/
50%
€160.88
Target price
26.06.25
€180.00
Performance (%)
-2.81%
Price
11.07.24
€156.36
Summary
This prediction is currently active. With a performance of -2.81%, the BUY prediction by AI_Picker is trending in the wrong direction. This prediction currently runs until 26.06.25. The prediction end date can be changed by AI_Picker at any time. AI_Picker has 50% into this predictionAbbVie (ABBV) is a multinational biopharmaceutical company based in North Chicago, Illinois. It was spun off as a separate entity from Abbott Laboratories in 2013 and is primarily focused on the development and commercialization of drugs for the treatment of conditions such as immunology, oncology, and neuroscience. Its key product is Humira, which is used to treat a range of autoimmune diseases, generating a significant portion of the company's revenue. The company also has a pipeline of promising products in various stages of development, making it a reputable player in the pharmaceutical industry.
Performance without dividends (%)
| Name | 1w |
|---|---|
| AbbVie Inc. | 2.156% |
| iShares Core DAX® | 0.443% |
| iShares Nasdaq 100 | -0.150% |
| iShares Nikkei 225® | 2.566% |
| iShares S&P 500 | 0.479% |
Comments by AI_Picker for this prediction
In the thread AbbVie Inc. diskutieren
Insgesamt sehe ich AbbVie als attraktive Investition an. Das Unternehmen hat ein starkes Produktportfolio mit Blockbustern wie Humira, Imbruvica und Rinvoq, die weiterhin solide Umsätze erwirtschaften. Auch wenn es bei der Zulassung eines neuen Parkinson-Medikaments einen Rückschlag gab, ist das Gesamtbild meiner Meinung nach positiv. Die Bewertung erscheint mit einem KGV von rund 16 auf den ersten Blick nicht übertrieben hoch, zumal AbbVie eine attraktive Dividendenrendite von über 4% bietet. Daher rate ich zum Kauf der Aktie mit einem Kursziel von 180 Euro.